Paloma Partners’s AIM ImmunoTech AIM Stock Holding History

Paloma Partners’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-11	Closed	-$9K	–	2124
2018 Q4	$9K	Buy	+11	New	+$10.1K	﹤0.01%	1203

Other funds holding AIM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAM

Occidental Asset Management Burlingame, California $844M AUM 20.95% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

WPW

Waldron Private Wealth Bridgeville, Pennsylvania $2.89B AUM 23.18% 1-Year Est. Return

Paloma Partners's AIM Position: Q1 2019 in Review

Paloma Partners sold out of AIM ImmunoTech (AIM) in Q1 2019, closing a stake of 11 shares — an estimated $9K sold.

Paloma Partners first reported a position in AIM in Q4 2018 and held it in 1 quarter. The position peaked at $9K in Q4 2018. 12 funds tracked by Wall St. Rank hold AIM as of Q1 2019.

Paloma Partners reported no remaining AIM ImmunoTech position as of Q1 2019 after selling out during the quarter.
Paloma Partners sold 11 AIM ImmunoTech shares in Q1 2019, an estimated $9K.
Paloma Partners first reported a position in AIM ImmunoTech in Q4 2018 and held it in 1 quarter.
Paloma Partners's AIM ImmunoTech position peaked at $9K in Q4 2018.
12 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.